Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Meridian Bioscience's Enterprise Value is $1,444.5 Mil.
Meridian Bioscience's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $55.5 Mil. Therefore, Meridian Bioscience's EV-to-EBIT ratio for today is 26.02.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Meridian Bioscience's Enterprise Value is $1,444.5 Mil.
Meridian Bioscience's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $72.0 Mil. Therefore, Meridian Bioscience's EV-to-EBITDA ratio for today is 20.06.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Meridian Bioscience's Enterprise Value is $1,444.5 Mil.
Meridian Bioscience's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 was $333.0 Mil. Therefore, Meridian Bioscience's EV-to-Revenue ratio for today is 4.34.
Meridian Bioscience Enterprise Value Historical Data
The historical data trend for Meridian Bioscience's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Meridian Bioscience's Enterprise Value
For the Diagnostics & Research subindustry, Meridian Bioscience's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meridian Bioscience's Enterprise Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Meridian Bioscience's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Meridian Bioscience's Enterprise Value falls into.
Meridian Bioscience Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Meridian Bioscience's Enterprise Value for the fiscal year that ended in Sep. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meridian Bioscience (NAS:VIVO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Meridian Bioscience's current Enterprise Value is $1,444.5 Mil.
Meridian Bioscience's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $55.5 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Meridian Bioscience's current Enterprise Value is $1,444.5 Mil.
Meridian Bioscience's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $72.0 Mil.
Meridian Bioscience's current Enterprise Value is $1,444.5 Mil.
Meridian Bioscience's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $333.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meridian Bioscience Enterprise Value Related Terms
Thank you for viewing the detailed overview of Meridian Bioscience's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Meridian Bioscience (Meridian Bioscience) Business Description
Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIVO has been successfully added to your 